Allogeneic adenovirus-specific cytotoxic T lymphocytes (MD Anderson Cancer Center)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameAllogeneic adenovirus-specific cytotoxic T lymphocytes (MD Anderson Cancer Center)
Drug Alias NameAllogeneic adenovirus-specific CTLs (MD Anderson Cancer Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulants
TargetsUpdating
Therapy Area/IndicationsAdenoviridae Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsAdenoviridae Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A